Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Capital Expenditures: 2015-2025

Historic Capital Expenditures for Voyager Therapeutics (VYGR) over the last 11 years, with Sep 2025 value amounting to $207,000.

  • Voyager Therapeutics' Capital Expenditures fell 19.77% to $207,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year decrease of 48.43%. This contributed to the annual value of $3.5 million for FY2024, which is 8.14% up from last year.
  • As of Q3 2025, Voyager Therapeutics' Capital Expenditures stood at $207,000, which was down 81.27% from $1.1 million recorded in Q2 2025.
  • In the past 5 years, Voyager Therapeutics' Capital Expenditures ranged from a high of $2.1 million in Q1 2024 and a low of $155,000 during Q4 2024.
  • Moreover, its 3-year median value for Capital Expenditures was $755,000 (2023), whereas its average is $795,182.
  • Its Capital Expenditures has fluctuated over the past 5 years, first plummeted by 90.24% in 2021, then surged by 363.44% in 2022.
  • Over the past 5 years, Voyager Therapeutics' Capital Expenditures (Quarterly) stood at $347,000 in 2021, then skyrocketed by 168.88% to $933,000 in 2022, then declined by 19.08% to $755,000 in 2023, then tumbled by 79.47% to $155,000 in 2024, then fell by 19.77% to $207,000 in 2025.
  • Its last three reported values are $207,000 in Q3 2025, $1.1 million for Q2 2025, and $658,000 during Q1 2025.